|
|
|
15.08.25 - 23:06
|
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on July 22, 2025, the Compensation Committee of Guardant's Board of Directors approved the granting of restricted stock units (“RSUs”) representing 239,565 shares of its common stock to 189 new non-executive employees and two non-qualified stock option awards to purchase 23,542 shares of its common stock to two new non-executive employees with a grant date of August 1, 2025 under the Guardant Health, Inc. 2023 Employment Inducement Incentive Award Plan (the “Inducement Plan”). The RSUs and stock options were granted as inducements material to the employees entering into employment with Guardant in accordance with Nasdaq Listing Rule 5635(c)(4).
The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Guardant, or following a bona fide period of non-employment, as an inducement material to such individua...
|
|
|
|
|
|
|
|
|
31.07.25 - 04:30
|
Guardant Health und James Van Der Beek schließen sich zusammen, um das Bewusstsein für neue Fortschritte bei der Darmkrebsvorsorge für Erwachsene ab 45 Jahren zu schärfen (Business Wire)
|
|
|
75 % der Patienten, die an Darmkrebs sterben, wurden nicht untersucht, oft weil die herkömmlichen Optionen als unangenehm oder unbequem empfunden werden
Das von der FDA zugelassene Shield-Produkt von Guardant bietet Erwachsenen ab 45 Jahren mit durchschnittlichem Darmkrebsrisiko eine Vorsorgeuntersuchung mittels einer einfachen Blutentnahme bei einem verschreibenden Arzt
Nach seiner Darmkrebsdiagnose setzt sich Van Der Beek erstmals öffentlich dafür ein, dass mehr Menschen Vorsorgeuntersuchungen in Anspruch nehmen
PALO ALTO, Kalifornien--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), ein führendes Unternehmen im Bereich der Präzisionsonkologie, gab heute seine Partnerschaft mit dem Schauspieler und Gesundheitsaktivisten James Van Der Beek bekannt, um das Bewusstsein für Darmkrebsvorsorge und den Shield™-Bluttest zu erhöhen. Shield wurde im vergangenen Jahr von der US-amerikanischen Arzneimittelbehörde FDA zugelassen und bietet eine bequeme und angenehmere neue Option für die Darmkrebsv...
|
|
|
|
|
|
|
30.07.25 - 22:06
|
Guardant Health Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance (Business Wire)
|
|
|
Revenue growth of 31% broadly driven by strong performance across Oncology, Screening, and Biopharma & Data
Raises 2025 revenue guidance to $915 to $925 million, representing growth of 24% to 25%PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended June 30, 2025.
Second Quarter 2025 Financial Highlights
For the three-month period ended June 30, 2025, as compared to the same period of 2024:
Reported total revenue of $232.1 million, an increase of 31%, driven by:
Oncology revenue of $158.7 million, an increase of 22%, and approximately 64,000 oncology tests, an increase of 30%
Screening revenue of $14.8 million, and approximately 16,000 Shield screening tests
Biopharma & Data revenue of $56.0 million, an increase of 28%
Generated non-GAAP gross margin of 66%, compared to 60% in the second quarter of 2024
Guardant360 Tissue average selling price increased to approximately $2,000, achieving 2028 targ...
|
|
|
30.07.25 - 14:12
|
Guardant Health and James Van Der Beek Team Up to Raise Awareness About New Advances in Colorectal Cancer Screening for Adults 45+ (Business Wire)
|
|
|
75% of patients who die from colorectal cancer (CRC) are not screened, often because traditional options are viewed as unpleasant or inconvenient
Guardant's FDA-approved Shield offers screening with a simple blood draw from any prescribing healthcare provider for adults 45+ at average risk for CRC
After a CRC diagnosis, Van Der Beek is speaking up for the first time to advocate to get more people screened
PALO ALTO, Calif.--(BUSINESS WIRE)--$GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its partnership with actor and health advocate James Van Der Beek to increase awareness about colorectal cancer (CRC) screening and the Shield™ blood test. Approved by the U.S. Food and Drug Administration (FDA) last year, Shield offers a convenient and more pleasant new option for CRC screening for eligible individuals 45+.
Known for iconic roles in Varsity Blues, Rules of Attraction and Don't Trust the B in Apartment 23, Van Der Beek has created many memorable character...
|
|
|
|
|
|
|
14.07.25 - 14:03
|
Guardant Health to Report Second Quarter 2025 Financial Results on July 30, 2025 (Business Wire)
|
|
|
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2025 after market close on Wednesday, July 30, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Live audio of the webcast will be available on the “Investors” section of the company website at: www.guardanthealth.com. The webcast will be archived and available for replay after the event.
About Guardant Health
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including s...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
